LACHMAN CONSULTANT SERVICES, INC.

CONSULTANTS TO THE PHARMACEUTICAL AND ALLIED INDUSTRIES

1600 STEWART AVENUE, WESTBURY, NY 11590
(516) 222-6222 • FAX (516) 683-1887

2175 7 MAR 30 A9:47

March 29, 2007

OVERNIGHT COURIER 03/29/07

Division of Dockets Management
Food and Drug Administration (HFA-305)
Department of Health and Human Services
5630 Fishers Lane, Room 1061
Rockville, MD 20852

WITHDRAWAL REQUEST FOR CITIZEN PETITION
2006p-0103/CP1 Temazepam, 7.5 mg, 15 mg, 22.5 mg and 30 mg

Dear Sir or Madam:

The undersigned submitted the above-referenced petition on March 9, 2006, in quadruplicate, pursuant to Section 505(j)(2)(C) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 355(j)(2)(C) and 21 C.F.R. §§ 10.20, 10.30 and 314.93. The petition was submitted on behalf of a client and requesting the Commissioner of the Food and Drug Administration to make a determination that an Abbreviated New Drug Application (ANDA) may be submitted for Temazepam Orally Disintegrating Tablets, 7.5 mg, 15 mg, 22.5 mg, and 30 mg. At this time we request that this petition be withdrawn without prejudice for refiling.

Respectfully submitted,

Robert Pollock

Robert W. Pollock
Senior Vice President

RWP/pk

cc: Craig Kiester, Office of Generic Drugs

M03P7088

2006P-0103

WDL 1